Epilepsy Therapeutics Market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Published By:Zion <strong>Market</strong> Research<br />
<strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong> : Increasing prevalence<br />
of neurological disorders drives the market by 2015 -<br />
2021<br />
Contact Us:<br />
4283, Express Lane, Suite 634-143,<br />
Sarasota, Florida 34249, United States<br />
Tel: +1-386-310-3803 GMT<br />
Tel: +49-322 210 92714<br />
USA/Canada Toll Free No.1-855-465-4651<br />
sales@zionmarketresearch.com
<strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
<strong>Epilepsy</strong> is a chronic neurological disorder characterized by unpredictable seizures. <strong>Epilepsy</strong> is<br />
the fourth most common neurological disorder that affects peoples of all age group. Seizures<br />
may be classified as focal seizures, generalized seizures, and other seizures. Focal seizures are<br />
the most common type of epilepsy which involves secondary generalized tonic/clonic seizures<br />
(sGTCS) and complex partial seizures. Generalized seizures include myoclonic seizures, tonic<br />
seizures, atonic seizures, absences, and clonic seizures. These seizures occur when neurons in<br />
the brain or a group of nerve cells send wrong signals to the body.<br />
Browse the full " <strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong>" report<br />
at https://www.zionmarketresearch.com/report/epilepsy-therapeutics-market<br />
Treatment of epilepsies is done by using antiepileptic drugs (AEDs). Antiepileptic drugs are<br />
segmented into two major categories namely first generation AEDs and second generation<br />
AEDs. Selection of drugs is done by prescriber depending upon the type of seizure, part of brain<br />
involved in epilepsy, age of patient.
<strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
<strong>Epilepsy</strong> therapeutic drug market is mostly driven by increasing prevalence of neurological<br />
disorders and technological advancements across many countries. Moreover, increasing<br />
awareness about diagnostics and treatment of neurological disorders in global market also help<br />
in driving the epileptic market growth. Non availability of medical facilities in poor and<br />
developing countries can restrict or hinder the growth of epileptic therapeutic market over the<br />
years. Conversely, the prescribing pattern of drugs that give preference to first generation AEDs<br />
over second generation AEDs is restraining the epilepsy therapeutics market. Nonetheless,<br />
ongoing research and development in the healthcare literacy rate are expected to open growth<br />
avenues for the market over the years.<br />
Request sample report at https://www.zionmarketresearch.com/sample/epilepsytherapeutics-market<br />
The report covers forecast and analysis of the epileptic therapeutic market on a global and<br />
regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021<br />
based on revenue (USD Million). To understand the competitive landscape in the market, an<br />
analysis of Porter’s Five Forces model for the epileptic therapeutic drug market has also been
<strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
included in the study. The report also analyzes several driving and restraining factors and their<br />
impact on the market during the forecast period. The study encompasses a market attractiveness<br />
analysis, wherein type segments are benchmarked based on their market size, growth rate and<br />
general attractiveness.<br />
The report provides detailed segmentation of the epileptic therapeutic drug market based on<br />
type and regional segment.<br />
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin<br />
America, and Middle East & Africa. Demand has been analyzed and forecast based on the<br />
current trends for the period of six years. North America & Europe were the leading regional<br />
segments of the epileptic therapeutic drug market due to availability of second generation<br />
antiepileptic drug.<br />
Three new AEDs have been approved in the U.S. since 2012 including ezogabine/retigabine,<br />
perampanel and eslicarbazepine acetate. Ezogabine/retigabine and perampanel among these<br />
have new mechanism of action and thus it is capturing good amount of market share in the U.S.
<strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
The epileptic therapeutic market is expected to witness the highest growth in the Asia-Pacific<br />
region in the coming years due to high prevalence of epilepsy in India and China, increasing<br />
health care infrastructure, incomes and awareness.<br />
Key players in epileptic therapeutic market include Abbott Laboratories, GlaxoSmithKline plc,<br />
Cephalon, Inc., Johnson & Johnson, Pfizer, Inc., Novartis AG, Sunovion Pharmaceuticals, Inc..,<br />
Valeant Pharmaceuticals International, Inc., Sanofi S.A. and Shire.<br />
This report segments the epileptic therapeutic market are:-<br />
Epileptic Therapeutic <strong>Market</strong>: Type Segment Analysis<br />
<br />
<br />
First Generation<br />
Second Generation<br />
Epileptic Therapeutic <strong>Market</strong>: Regional Segment Analysis<br />
<br />
North America
<strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
<br />
<br />
<br />
<br />
Europe<br />
Asia pacific<br />
Latin America<br />
Middle east & Africa<br />
Browse the full " <strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong>" report<br />
at https://www.zionmarketresearch.com/report/epilepsy-therapeutics-market<br />
Zion <strong>Market</strong> Research<br />
Address: 4283, Express Lane, Suite 634-143, Sarasota, Florida 34249, United States<br />
Tel: +1-386-310-3803 GMT<br />
+49-322 210 92714 Tel: +1-855-465-4651 (US/CAN TOLL FREE)<br />
Email: sales@zionmarketresearch.comWeb:www.zionmarketresearch.com
Change language